Breaking News, Financial News

Financial Report: Catalent

IPO costs impact results

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Catalent   1Q Revenues: $418.3 million (+1%)   1Q Loss: $19.5 million (earnings were $1.5 million in 1Q13)   Comments: Revenue from the Oral Technologies segment was $261.1 million, up 1% in the quarter. Revenue from the Development and Clinical Services segment was $103.1 million, up 2%. Revenue from the Medication Delivery Solutions segment was $56.9 million, up 1%. Loss in the quarter was related to one-time IPO costs of $50.4 million....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters